{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:32:19Z","timestamp":1789162339650,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T00:00:00Z","timestamp":1371427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T00:00:00Z","timestamp":1371427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/bmt.2013.83","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T10:38:46Z","timestamp":1371465526000},"page":"1409-1414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT"],"prefix":"10.1038","volume":"48","author":[{"given":"S P","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Canals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Luang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Y","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Pohlreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Capria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,17]]},"reference":[{"key":"BFbmt201383_CR1","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen H et al. High dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomised European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR2","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","volume":"21","author":"S Montoto","year":"2007","unstructured":"Montoto S, Canals C, Rohatiner AZS, Taghipour G, Sureda A, Schmitz N et al. Long term follow up of of high dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukaemia 2007; 21: 2324\u20132331.","journal-title":"Leukaemia"},{"key":"BFbmt201383_CR3","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","volume":"25","author":"AZS Rohatiner","year":"2007","unstructured":"Rohatiner AZS, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remisssion: long-term follow-up. J Clin Oncol 2007; 25: 2554\u20132559.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR4","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1994.12.12.2527","volume":"12","author":"DL Darrington","year":"1994","unstructured":"Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC et al. Incidence and characterisation of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dosee chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527\u20132534.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","volume":"101","author":"C Metayer","year":"2003","unstructured":"Metayer C, Curtis RE, Vose JM, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicentre case-control study. Blood 2003; 101: 2015\u20132023.","journal-title":"Blood"},{"key":"BFbmt201383_CR6","first-page":"1832","volume":"92","author":"K van Besien","year":"1998","unstructured":"van Besien K, Sobocinski K, Rowlings P, Murphy SC, Armitage JO, Bishop MR et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832\u20131836.","journal-title":"Blood"},{"key":"BFbmt201383_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"AJ Peniket","year":"2003","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667\u2013678.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201383_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bbmt.2009.01.012","volume":"15","author":"K van Besien","year":"2009","unstructured":"van Besien K, Carreras J, Bierman PJ, Logan B, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554\u2013563.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201383_CR9","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O\u2019Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817\u20132824.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR10","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","volume":"89","author":"S Giralt","year":"1997","unstructured":"Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531\u20134536.","journal-title":"Blood"},{"key":"BFbmt201383_CR11","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530\u20135536.","journal-title":"Blood"},{"key":"BFbmt201383_CR12","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin\u2019s lymphoma (NHL). Blood 2004; 104: 3865\u20133871.","journal-title":"Blood"},{"key":"BFbmt201383_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008; 26: 211\u2013217.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3324\/haematol.10924","volume":"92","author":"S Vigouroux","year":"2007","unstructured":"Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92: 627\u2013634.","journal-title":"Haematologica"},{"key":"BFbmt201383_CR15","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","volume":"95","author":"JL Pinana","year":"2010","unstructured":"Pinana JL, Martino R, Gayoso J, Sureda A, Serna J, Diez-Martin JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicentre trials. Haematologica 2010; 95: 1176\u20131182.","journal-title":"Haematologica"},{"key":"BFbmt201383_CR16","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/jco.2008.26.15_suppl.7041","volume":"26","author":"G Laport","year":"2008","unstructured":"Laport G, Bredeson C, Tomblyn MR, Kahl BS, Goodman SA, Ewell M et al. Autologous versus reduced intensity allogeneic hematopoietic cell transplantation for patients with follicular non Hodgkin\u2019s lymphoma beyond first complete response. J Clin Oncol 2008; 26: 15s (suppl; abstr 7041).","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR17","unstructured":"European Bone Marrow Transplant Registry. Operational manual. http:\/\/www.ebmt.org\/4Registry\/Registry docs\/MEDAB%20Manual.pdf."},{"key":"BFbmt201383_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","volume":"113","author":"E Gyan","year":"2009","unstructured":"Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009; 113: 995\u20131001.","journal-title":"Blood"},{"key":"BFbmt201383_CR19","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540\u20132544.","journal-title":"Blood"},{"key":"BFbmt201383_CR20","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667\u20132674.","journal-title":"Blood"},{"key":"BFbmt201383_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","volume":"21","author":"JO Armitage","year":"2003","unstructured":"Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients. J Clin Oncol 2003; 21: 897\u2013906.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR22","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt201383_CR23","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt201383_CR24","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","volume":"21","author":"PJ Bierman","year":"2003","unstructured":"Bierman PJ, Sweetenham JW, Loberiza FM, Fausto R, Taghipour G, Lazarus HM et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma: a comparison with allogeneic and autologous transplantation. J Clin Oncol 2003; 21: 3744\u20133753.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","volume":"36","author":"NH Russell","year":"2005","unstructured":"Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP . Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 437\u2013441.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201383_CR26","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","volume":"32","author":"CM Mandigers","year":"2003","unstructured":"Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schaltenberg B, Raemaekers JMM . Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32: 1159\u20131163.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201383_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","volume":"14","author":"AJ Bloor","year":"2008","unstructured":"Bloor AJ, Thomson K, Chowdhry N, Verfeuth S, Ings S, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50\u201358.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201383_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/leu.2010.292","volume":"25","author":"J Delgado","year":"2010","unstructured":"Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia 2010; 25: 551\u2013555.","journal-title":"Leukemia"},{"key":"BFbmt201383_CR29","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","volume":"20","author":"K Branson","year":"2002","unstructured":"Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022\u20134031.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR30","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","volume":"28","author":"K Thomson","year":"2010","unstructured":"Thomson K, Morris E, Milligan D, Parker A, Hunter AE, Cook G et al. T-cell-depleted reduced intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695\u20133700.","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR31","doi-asserted-by":"publisher","first-page":"7s","DOI":"10.1200\/jco.2010.28.15_suppl.8005","volume":"28","author":"R Pettengel","year":"2010","unstructured":"Pettengel R, Schmitz N, Gisselbrecht C, Caballero D, Colombat P, Conde E et al. Randomised study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol 2010; 28: 7s (suppl;abstr 8005).","journal-title":"J Clin Oncol"},{"key":"BFbmt201383_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417\u20131423.","journal-title":"Blood"},{"key":"BFbmt201383_CR33","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u20133732.","journal-title":"Blood"},{"key":"BFbmt201383_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"GA Salles","year":"2011","unstructured":"Salles GA, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with untreated high tumour burden follicular lymphoma after response to immunochemotherapy. Lancet 2011; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFbmt201383_CR35","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MHJ van Oers","year":"2006","unstructured":"van Oers MHJ, Klasa R, Marcus R, Wolf M, Kimby E, Gascoyne RD et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma in patients both with and without rituximab during induction: results of a prospective randomised phase 3 trial. Blood 2006; 108: 3295\u20133301.","journal-title":"Blood"},{"key":"BFbmt201383_CR36","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, Bock H-P, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective study of the German Low Grade Lymphoma Study Group. Blood 2006; 108: 4003\u20134008.","journal-title":"Blood"},{"key":"BFbmt201383_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"SJ Horning","year":"2005","unstructured":"Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D et al. Efficacy and safety of tositumumab and iodine-131 tositumumab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23: 712\u2013719.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201383","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:20:36Z","timestamp":1648056036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,17]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFbmt201383"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.83","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,17]]},"assertion":[{"value":"3 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}